MNPR Stock Summary and Trading Ideas (Monopar Therapeutics | NASDAQ:MNPR)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidivefor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics trades on the NASDAQ stock market under the symbol MNPR.

As of April 11, 2025, MNPR stock price climbed to $34.89 with 14,269 million shares trading.

MNPR has a beta of 2.71, meaning it tends to be more sensitive to market movements. MNPR has a correlation of 0.08 to the broad based SPY ETF.

MNPR has a market cap of $212.78 million. This is considered a Small Cap stock.

In the last 3 years, MNPR traded as high as $54.30 and as low as $1.37.

The top ETF exchange traded funds that MNPR belongs to (by Net Assets): VXF.

MNPR has outperformed the market in the last year with a return of +806.2%, while the SPY ETF gained +4.5%. In the last 3 month period, MNPR beat the market returning +37.6%, while SPY returned -7.7%. However, in the most recent 2 weeks MNPR has underperformed the stock market by returning -13.5%, while SPY returned -3.9%.

MNPR support price is $28.12 and resistance is $35.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNPR shares will trade within this expected range on the day.